Arpita Dutt | TalkMarkets | Page 5

Arpita Dutt

Analyst at Zacks Research Pvt. Ltd.
Contributor's Links: Zacks Investment Research
Arpita has been an equity analyst at Zacks Investment Research since March, 2004.
Following: 12 Followers: 1930

All Contributions

Latest Posts
65 to 80 of 92 Posts
<<< 1 ... 2 3 4 5 6 >>>
Biotech Stock Roundup: Clinical Holds Hit Inovio & Aduro, Vertex Q3 Results Miss Estimates
Wednesday, October 26, 2016 2:15 PM EDT
What's next in the Biotech world?
In this article: INO, ALKS, AMGN, BIIB, GILD, VRTX, ADRO
Read
7 Drug Stocks To Consider As Biosimilars Pick Up Pace
Thursday, October 20, 2016 1:53 PM EDT
Interest in biosimilars has picked up as Pfizer announced its plans to launch a biosimilar version of JNJ’s blockbuster drug, Remicade.
In this article: TEVA, BIIB, MNTA, MRK, NVS, AMGN, PFE
Read
Biotech Stock Roundup: Ariad Down On Drug Pricing Tweet, Regeneron Study On Clinical Hold
Wednesday, October 19, 2016 2:27 PM EDT
Shares of Ariad declined 14.8% after Senator Bernie Sanders tweeted on the company’s price hike of leukemia drug Iclusig.
In this article: ARIA, REGN, OCUL, PTCT, MDCO, VRTX, BIIB
Read
Will These 5 Drug Stocks Be Big Winners This Earnings Season?
Thursday, October 13, 2016 10:54 AM EDT
With the Medical sector expected to record earnings and revenue growth, it makes sense to select stocks from this sector that performed well in Q2 and are expected to do well in Q3.
In this article: ACHN, ARIA, EXEL, UTHR, ASND
Read
Biotech Stock Roundup: Alnylam Slumps On Revusiran Update, TESARO Impresses At ESMO
Wednesday, October 12, 2016 11:14 AM EDT
Alnylam focused on developing novel therapeutics based on RNA interference (RNAi), saw its shares slump on its decision to discontinue the development of a late-stage pipeline candidate.
In this article: ALNY, TSRO, CLVS, INCY, SRPT, BIIB, VRTX
Read
5 Stock Picks Ahead Of World Mental Health Day
Friday, October 7, 2016 2:08 PM EDT
The market potential for drugs targeting mental health disorders is huge.
In this article: GWPH, SHPG, JNJ, SUPN, AGN
Read
6 Best Performing Drug Stocks Of September 2016
Monday, October 3, 2016 12:05 PM EDT
Quite a few pharma and biotech stocks had an impressive run in the month of September thanks to acquisition announcements, positive data readouts, and FDA approvals. Here is a look at 6 of the best-performing drug stocks of September.
In this article: ARRY, CLVS, SRPT, VTAE, AERI, TBRA
Read
Biosimilars In Limelight On FDA Approval Of Amgen Drug
Tuesday, September 27, 2016 12:30 PM EDT
Late last week, the FDA approved yet another biosimilar product -- biotech giant Amgen Inc.’s Amjevita (adalimumab-atto).
In this article: SNY, LLY, AMGN, UNH, CVS, ESRX, ABBV
Read
The Internet Of Medical Things: 6 Stocks In Focus
Monday, September 26, 2016 12:20 PM EDT
The Internet of Medical Things is fast gaining pace as pharma companies look to innovate and keep up with technology to help patients and physicians better monitor and track diseases.
In this article: TEVA, INTC, SNY, GOOGL, QCOM, NVS, GSK
Read
Pharma Stock Roundup: Allergan Acquisitions In Focus, J&J To Buy Abbott's AMO
Friday, September 23, 2016 12:15 PM EDT
Once again, acquisitions and deals were in focus in the pharma sector with Allergan announcing a couple of back-to-back deals including one worth up to $1.695 billion.
In this article: AGN, JNJ, ABT Also: SNY, LLY, AZN, BMY
Read
5 Biotech Stocks To Watch As Interest In NASH Increases
Thursday, September 22, 2016 1:45 PM EDT
The market is suddenly abuzz about nonalcoholic steatohepatitis or NASH, a common but often “silent” liver disease. Several companies are working on developing treatments for NASH – the market could be worth billions of dollars.
In this article: ICPT, CNAT, GALT, ENTA, GLMD Also: AGN
Read
5 Biotech Stocks That Are Broker Favorites
Tuesday, September 13, 2016 1:12 PM EDT
It’s been a pretty rough year for the biotech sector with the Nasdaq Biotechnology index tumbling 18.7% over the last 12 months and 12.3% year-to-date (YTD).
In this article: LGND, AVEO, IMUC, FATE Also: PFE, MYL
Read
3 Drug Stocks That Could Benefit From Key FDA Events In Sep. 2016
Monday, September 12, 2016 1:25 PM EDT
The drug development process is often lengthy and time-consuming and requires the utilization of a lot of funds and resources. It may well take a drug anything between 10-12 years to be successfully developed and reach the market.
In this article: VRTX, AMGN, SPPI Also: ABBV
Read
6 Drug Stocks In Focus As Zika Virus Fear Spreads
Tuesday, September 6, 2016 9:44 AM EDT
Here is a look at some companies that are involved in the fight against Zika and stand to benefit if they are successful in their efforts.
In this article: GSK, SNY, SPB, INO, OSUR, TKPYY
Read
Pfizer-Medivation Close To Signing $14B Acquisition Deal?
Monday, August 22, 2016 5:24 AM EDT
Pfizer Inc. and Medivation, Inc. are close to signing a deal under which Pfizer will acquire Medivation for more than $80 per share (approximately $14 billion).
In this article: PFE, MDVN Also: SNY, ALIOF
Read
J&J's Depression Treatment Esketamine Gets BTD
Wednesday, August 17, 2016 10:33 AM EDT
Johnson & Johnson's Janssen Research & Development, LLC announced that the FDA has granted Breakthrough Therapy Designation to esketamine, an experimental antidepressant treatment.
In this article: JNJ Also: ALIOF, GERN, ABBV
Read
65 to 80 of 92 Posts
<<< 1 ... 2 3 4 5 6 >>>